BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren’s contracture and also for Peyronie's disease in Europe and Australia.

Endo has the following partnerships outside the U.S. for these two indications; Swedish Orphan Biovitrum AB has marketing rights for Xiapex® (the European tradename for XIAFLEX) in certain Eurasian countries and Asahi Kasei Pharma Corporation has marking rights in Japan. Sobi is selling Xiapex in Europe for the treatment of Dupuytren's contracture and Peyronie's disease. Asahi is selling XIAFLEX for the treatment of Dupuytren's contracture in Japan. The XIAFLEX research and development pipeline includes several additional promising indications. Endo is currently managing development for cellulite, adhesive capsulitis, human and canine lipomas, lateral hip fat and plantar fibromatosis. Endo expects to initiate Phase 3 clinical trials of XIAFLEX for the treatment of cellulite by the first quarter of 2018. BioSpecifics is managing the development of XIAFLEX for uterine fibroids. A Phase 1 clinical trial is ongoing with data expected in 2018.